Success Metrics

Clinical Success Rate
93.8%

Based on 61 completed trials

Completion Rate
94%(61/65)
Active Trials
13(15%)
Results Posted
69%(42 trials)
Terminated
4(5%)

Phase Distribution

Ph not_applicable
3
4%
Ph phase_2
27
32%
Ph early_phase_1
1
1%
Ph phase_1
8
10%
Ph phase_4
2
2%
Ph phase_3
43
51%

Phase Distribution

9

Early Stage

27

Mid Stage

45

Late Stage

Phase Distribution84 total trials
Early Phase 1First-in-human
1(1.2%)
Phase 1Safety & dosage
8(9.5%)
Phase 2Efficacy & side effects
27(32.1%)
Phase 3Large-scale testing
43(51.2%)
Phase 4Post-market surveillance
2(2.4%)
N/ANon-phased studies
3(3.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

92.4%

61 of 66 finished

Non-Completion Rate

7.6%

5 ended early

Currently Active

13

trials recruiting

Total Trials

84

all time

Status Distribution
Active(14)
Completed(61)
Terminated(5)
Other(4)

Detailed Status

Completed61
Recruiting13
Terminated4
unknown4
Not yet recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
84
Active
13
Success Rate
93.8%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (1.2%)
Phase 18 (9.5%)
Phase 227 (32.1%)
Phase 343 (51.2%)
Phase 42 (2.4%)
N/A3 (3.6%)

Trials by Status

terminated45%
recruiting1315%
completed6173%
not_yet_recruiting11%
unknown45%
withdrawn11%

Recent Activity

Clinical Trials (84)

Showing 20 of 84 trialsScroll for more
NCT07265479Phase 3

A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

Recruiting
NCT06959225Phase 3

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)

Recruiting
NCT06958211Phase 3

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)

Recruiting
NCT07013201Phase 2

A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis

Recruiting
NCT06286397Phase 2

Topical Anti-Androgens in Pilonidal Sinus Disease

Recruiting
NCT07426120Phase 3

Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III)

Recruiting
NCT04845620Phase 3

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)

Completed
NCT06548360Phase 3

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo

Recruiting
NCT06832618Phase 3

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

Recruiting
NCT05764161Phase 3

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)

Completed
NCT06804811Phase 3

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo

Recruiting
NCT07186413Phase 3

A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris

Recruiting
NCT05755438Phase 3

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)

Completed
NCT06238817Phase 3

A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis

Completed
NCT06004050Phase 3

A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema

Completed
NCT05014568Phase 3

Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults

Completed
NCT06631170Phase 3

Efficacy and Safety of Roflumilast Cream in Subjects With Atopic Dermatitis

Completed
NCT05032859Phase 3

Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102)

Completed
NCT04896385Phase 2

A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA)

Completed
NCT06403501Phase 3

Efficacy and Safety of Clascoterone Cream 1% in Facial Acne Vulgaris

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
84